Episodit
-
Chris Barden, a co-managing partner at MPM Bioimpact who manages the firmâs Bioimpact Equities and Oncology Impact funds, shares her insights into the upcoming American Society of Clinical Oncology (ASCO) conference in Chicago. She talks about the major trends in oncology, including development of antibody drug conjugates, which is currently the hottest area in cancer treatment. Another highlight she expects from ASCO will be development in radiotherapy treatments, particularly in prostate cancer. Bardon provides a guide for attendees to use in setting their schedules for the yearâs biggest cancer conference and what to watch for in the future.
-
A non-traditional route for financing has been the path to success for Fibrobiologics Inc. In the newest BioWorld Insider podcast, CEO Pete OâHeeron offers insight into the companyâs unusual path to a Nasdaq listing in January. SPACs, reverse mergers and traditional IPOs werenât attractive enough for Fibrobiologicsâ management or board, so they decided to go public through a direct listing with no banks as underwriters. It took about seven months to get the company ready for its listing, an around-the-clock effort that OâHeeron said was worth the effort. âWe couldnât be more happy with the outcome,â he said.
-
Puuttuva jakso?
-
BioWorld Managing Editor Karen Carey joins the podcast to talk about the numbers from the first quarter of 2024, along with a look back at some 2023 deals and indicators that signal better times are on the way. Financings for the quarter were better than expected, sporting some of the best numbers of the past 13 years. Itâs part of a larger trend, Carey says, of investors being a lot pickier about where they put their money and demanding better data. The result is a strengthened market and a better outlook.
-
In one of the biggest financings of the year so far, former Prometheus Biosciences Inc. CEO Mark McKenna helped raise $400 million to launch a new company, Mirador Therapeutics Inc. He didnât sit on the sidelines for long after Merck & Co. Inc. bought Prometheus for $10.8 billion in 2023. He recruited key Prometheus executives to focus on Miradorâs genetic approach to drug discovery and precision medicine. McKenna said there was too much left undone to just hang back. In this BioWorld Insider episode, he talks about the new company and the multi-billion-dollar drugs that he believes provide sub-optimal efficacy compared to the tailor-made therapies he wants to develop. He also has deep insights into drug pricing and why the investment market is so tough on companies that donât have A-plus science and teams.
-
Because artificial intelligence is such a new technology it comes with a mountain of unknowns. Integrating it into a pharmaceutical company presents a unique series of challenges, as a new survey from Verix shows. The report is based on responses from directors, vice presidents and C-suite executives in sales, marketing and brand management at pharmaceutical companies in the U.S. that have more than $100 million in annual revenue. Doron Aspitz, the CEO of Verix, talked about the new findings with the BioWorld Insider podcast and the profound shift that executives face as the new technology takes over an entire industry.
-
One aspect of 2023 our group of executives completely agreed on: the past year was tough financially. And they all foresee a more vibrant year ahead for the market. Giving all of them hope were technological breakthroughs such as artificial intelligence, game changing weight loss drugs, the surging fascination with ADCs and hope for lower interest rates. But uncertainty looms about the upcoming general election in the U.S. and ground-shifting gene therapies. In a preview of the annual Biotech Showcase conference, an investor conference for private and micro- to mid-cap biotech companies Jan. 8-10 in San Francisco, BioWorld spoke with Dave Bearss, CEO of Halia Therapeutics Inc., Vimal Mehta, CEO of Bioxcel Therapeutics Inc., Paul Lammers, CEO at Triumvira Immunologics Inc., Chris Pirie, COO of HDT Bio Corp., Thijs Spoor, CEO of Perspective Therapeutics Inc. and Shelley Hartman, CEO of Aegle Therapeutics Corp. They offered insights brought about by years of hard-won experience.
-
Googleâs Scott Penberthy joins the podcast for a visionary discussion that scans the horizon for startling changes artificial intelligence will bring to drug development in the relatively near future. Among the gems and eyebrow raisers is talk of dramatic reductions in the time it takes to identify the right molecule for development and how digital clinical trials in the not-too-distant future will substantially shrink study times. This episode also provides a preview of the annual Biofuture conference. Each year, a group of trailblazers, disruptors and forward-thinking executives converge to evaluate and forecast the future of health care. This year, BioWorld is a gold sponsor of the Oct. 4-6 event in New York. If you attend, you'll have the chance to hear panels and join workshops and fireside chats with key opinion leaders like Penberthy.
-
Guests Karen Carey, BioWorldâs managing editor, and Mike Ward, Clarivateâs global head of Life Sciences and Healthcare Thought Leadership, discuss the deals, financing and M&A landscape for the first half of 2023 and how U.K. biopharmas are faring post Brexit.
-
Guests BioWorld Regulatory Editor Mari Serebrov and Tom Newcomer, Samsung Bioepis vice president and head of U.S. market access, discuss the launch of biosimilars that are taking on a blockbuster.
-
Brad Holden, CEO of Resilient Lifescience, explains how the device works for overdoses as well as other potential applications for this new technology.
-
BioWorld Staff Writer Tamra Sami talks about the science behind radiopharmaceuticals, the supply chain vulnerabilities, the regulatory landscape, the patient journey and therapies in the pipeline.
Hosted on Acast. See acast.com/privacy for more information.
-
Guests Karen Zaderej, CEO of Axogen Inc., Sean Bohen, CEO of Olema Oncology Inc., Rob Ross, the CEO of Surface Oncology Inc., and Rob Etherington, the CEO of Clene Nanomedicine Inc., speak about adapting their companies to the marketâs new realities.
Hosted on Acast. See acast.com/privacy for more information.
-
BioWorld Senior Analyst Karen Carey chats about the collision of a volatile economic climate and big biopharma deals.
Hosted on Acast. See acast.com/privacy for more information.
-
Extending the human lifespan, a BioWorld special report, examines the companies developing âFountain of Youthâ drugs. In this episode, the writers discuss this scientific holy grail.
Hosted on Acast. See acast.com/privacy for more information.
-
BioWorld Senior Analyst Karen Carey explores the newest data and where it is leading.
Hosted on Acast. See acast.com/privacy for more information.
- Näytä enemmän
